Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02920177 · ClinicalTrials.gov registry record · Phase 4
Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement
A Phase 4 study, sponsored by University of Michigan.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT02920177: Clinical Trial Phase 4 study, sponsored by University of Michigan.
NCT02920177 is a Phase 4 study that was terminated before completion, run by University of Michigan. The registered enrollment target is 4 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02920177, a Phase 4 study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the clinical response of intra-articular platelet rich plasma (PRP) versus corticosteroid injection in patients affected by femoroacetabular impingement (FAI).
Primary Outcome
VAS score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity.
Interventions
- DRUG platelet-rich plasma injection
- DRUG Kenalog 10 MG/ML Injectable Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2018-08-10 |
| Phase | Phase 4 |
Why NCT02920177 stopped before completion
NCT02920177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which platelet-rich plasma injection is the first listed.
NCT02920177 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02920177 about?
NCT02920177 is a clinical study titled "Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement". The purpose of this study is to compare the clinical response of intra-articular platelet rich plasma (PRP) versus corticosteroid injection in patients affected by femoroacetabular impingement (FAI).
What is the current status of trial NCT02920177?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2016-08-01. Estimated completion is 2018-08-10.
What interventions are being tested in trial NCT02920177?
The interventions under investigation include: platelet-rich plasma injection (DRUG), Kenalog 10 MG/ML Injectable Suspension (DRUG).
Who is sponsoring clinical trial NCT02920177?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02920177's enrollment target sits among peer trials
4 1994th of 2000 higher than 6 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI